Reduction of Gadolinium in brain MRI up to 80% with deep learning methods

Contrast agents, such as Gadolinium-based contrast agents (GBCAs), are often used to enhance the clarity of MRI images. However, GBCAs have been linked to various forms of toxicity and have been found to accumulate in brain tissue. In addition, certain patient groups, including those with kidney issues, children, and pregnant women, may be unable to receive the full dose of GBCAs due to sensitivity concerns. As a result, there is a need for methods that can reduce the dose of GBCAs while maintaining diagnostic accuracy. At DeepMeds, we are dedicated to addressing this need through the use of state-of-the-art deep learning technology to provide cost-effective and safer contrast-enhanced medical imaging exams

What DeepMeds does?

DeepMeds is a leading provider of deep learning-based software for medical imaging. Our solution can reduce the use of contrast agents, such as Gadolinium-based contrast agents (GBCAs), by up to 80%, saving hospitals and clinics money and improving patient safety. Our algorithm has the ability to enhance the contrast of images taken with a reduced dose of contrast agent to the same level as those taken with a full dose, making it a valuable tool for improving diagnostic accuracy and reducing the risks associated with GBCAs. If you are looking for a cost-effective and safer alternative for contrast-enhanced medical imaging exams, consider using DeepMeds